Neuromelanin of the human substantia nigra: an update
- PMID: 24155156
- DOI: 10.1007/s12640-013-9435-y
Neuromelanin of the human substantia nigra: an update
Abstract
Dopaminergic neurons of the substantia nigra selectively degenerate over the course of Parkinson's disease. These neurons are also the most heavily pigmented cells of the brain, accumulating the dark pigment neuromelanin over a lifetime. The massive presence of neuromelanin in these brain areas has long been suspected as a key factor involved in the selective vulnerability of neurons. The high concentration of neuromelanin in substantia nigra neurons seems to be linked to the presence of considerable amounts of cytosolic dopamine that have not been sequestered into synaptic vesicles. Over the past few years, studies have uncovered a dual nature of neuromelanin. Intraneuronal neuromelanin can be a protective factor, shielding the cells from toxic effects of redox active metals, toxins, and excess of cytosolic catecholamines. In contrast, neuromelanin released by dying neurons can contribute to the activation of neuroglia triggering the neuroinflammation that characterizes Parkinson's disease. This article reviews recent studies on the molecular aspects of neuromelanin of the human substantia nigra.
Similar articles
-
Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics.Trends Neurosci. 2003 Nov;26(11):578-80. doi: 10.1016/j.tins.2003.08.009. Trends Neurosci. 2003. PMID: 14585596 Review.
-
The enigma of neuromelanin in Parkinson's disease substantia nigra.J Neural Transm Suppl. 1994;43:113-22. J Neural Transm Suppl. 1994. PMID: 7884393 Review.
-
New face of neuromelanin.J Neural Transm Suppl. 2006;(70):119-23. doi: 10.1007/978-3-211-45295-0_19. J Neural Transm Suppl. 2006. PMID: 17017518 Review.
-
The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.J Neural Transm (Vienna). 2023 May;130(5):611-625. doi: 10.1007/s00702-023-02617-6. Epub 2023 Mar 20. J Neural Transm (Vienna). 2023. PMID: 36939908 Free PMC article. Review.
-
In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.Brain. 2016 Jul;139(Pt 7):2039-49. doi: 10.1093/brain/aww098. Epub 2016 May 5. Brain. 2016. PMID: 27190023
Cited by
-
Melanin and Melanin-Functionalized Nanoparticles as Promising Tools in Cancer Research-A Review.Cancers (Basel). 2022 Apr 6;14(7):1838. doi: 10.3390/cancers14071838. Cancers (Basel). 2022. PMID: 35406610 Free PMC article. Review.
-
"Reframing" dopamine signaling at the intersection of glial networks in the aged Parkinsonian brain as innate Nrf2/Wnt driver: Therapeutical implications.Aging Cell. 2022 Apr;21(4):e13575. doi: 10.1111/acel.13575. Epub 2022 Mar 9. Aging Cell. 2022. PMID: 35262262 Free PMC article. Review.
-
Evidence for Dopamine Abnormalities Following Acute Methamphetamine Exposure Assessed by Neuromelanin-Sensitive Magnetic Resonance Imaging.Front Aging Neurosci. 2022 May 30;14:865825. doi: 10.3389/fnagi.2022.865825. eCollection 2022. Front Aging Neurosci. 2022. PMID: 35707702 Free PMC article.
-
Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson's disease.J Neuroinflammation. 2019 Feb 27;16(1):50. doi: 10.1186/s12974-019-1439-y. J Neuroinflammation. 2019. PMID: 30813952 Free PMC article.
-
Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?Front Neurosci. 2018 Mar 14;12:161. doi: 10.3389/fnins.2018.00161. eCollection 2018. Front Neurosci. 2018. PMID: 29593491 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous